Skip to main content

Table 2 Patient and tumor characteristics in patients tested for HRG

From: Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Characteristic

HRG-negative (n = 18)

HRG-positive (n = 14)

Age at study entry (years)

61.6 (15.0)

56.3 (10.1)

BMI (kg/m2)

25.6 (4.3)

24.9 (4.2)

Time from diagnosis to metastasis (years)

5.6 (5.8)

3.8 (4.4)

Tumor grade

 1

2 (11.8)

2 (18.2)

 2

11 (64.7)

7 (63.6)

 3

4 (23.5)

2 (18.2)

ECOG score

 0

13 (76.5)

11 (84.6)

 1

4 (23.5)

2 (15.4)

 2+

0 (0.0)

0 (0.0)

Concomitant diseases

 0 or 1

8 (44.4)

10 (76.9)

 2 to 4

10 (55.6)

2 (15.4)

 5+

0 (0.0)

1 (7.7)

Metastasis pattern

 Brain

0 (0.0)

1 (7.1)

 Visceral

4 (22.2)

9 (64.3)

 Bone

2 (11.1)

1 (7.1)

 Other

12 (66.7)

3 (21.4)

Ever received chemotherapy

 No

18 (100.0)

14 (100.0)

 Yes

0 (0.0)

0 (0.0)

Ever received endocrine therapy

 No

1 (5.6)

1 (7.1)

 Yes

17 (94.4)

13 (92.9)

Ever received fulvestrant

 No

18 (100.0)

14 (100.0)

 Yes

0 (0.0)

0 (0.0)

Previous CDK4/6i documented

 No

0 (0.0)

1 (7.1)a

 Yes

18 (100.0)

13 (92.9)

SHERBOC line

 1

17 (94.4)

12 (85.7)

 2

1 (5.6)

2 (14.3)

  1. BMI Body mass index; ECOG Eastern Cooperative Oncology Group; HRG Heregulin. CDK4/6i CDK4/6 inhibitor
  2. Means and standard deviation (SD) are shown for continuous characteristics, and frequency and percentage for categorical characteristics
  3. a This patient was confirmed to be clinically eligible for SHERBOC despite CDK4/6i was not documented yet at time of database closure